Evidence for a role for cyclic AMP in modulating the action of 5-HT and an excitatory neuropeptide, FLP17A, in the pharyngeal muscle of Caenorhabditis elegans.
The feeding activity of the nematode Caenorhabditis elegans is regulated by an anatomically well-defined network of 20 enteric neurones that employs small molecule and neuropeptidergic signalling. Two of the most potent excitatory agents are 5-HT and the neuropeptide FLP17A. Here we have examined the role of cAMP in modulating their excitatory actions by pharmacological manipulation of the level of cAMP. Application of the membrane permeable cAMP analogue, dibutyryl-cAMP (1 microM), enhanced the excitatory response to both FLP17A and 5-HT. Furthermore, the adenylyl cyclase activator, forskolin (50 nM), significantly enhanced the excitatory response to both FLP17A and 5-HT. The phosphodiesterase inhibitor, ibudilast (10 microM), enhanced the excitatory response to FLP17A. The protein kinase inhibitor, H-9 dihydrochloride (10 microM) significantly reduced the excitatory response to 5-HT. H-9 dihydrochloride also had a direct effect on pharyngeal activity. The effect of FLP17A and 5-HT on two mutants, egl-8 (loss-of-function phospholipase-Cbeta) and egl-30 (loss-of-function Galphaq) was also investigated. Both these mutants have a lower pharyngeal pumping rate than wild-type which has to be considered when interpreting the effects of these mutations on the excitatory responses to FLP17A and 5HT. However, even taking into consideration the lower basal activity of these mutants, it is clear that the percentage increase in pharyngeal pumping rate induced by FLP17A is greatly reduced in both mutants compared to wild-type. In the case of 5-HT, the effect of the mutant backgrounds on the response was less pronounced. Overall, the data support a role for cAMP in modulating the excitatory action of both FLP17A and 5-HT on C. elegans pharyngeal pumping and furthermore implicate an EGL-30 dependent pathway in the regulation of the response to FLP17A.
Papaioannou
Sylvana
S
School of Biological Sciences, University of Southampton, Bassett Crescent East, Southampton, UK.
Holden-Dye
Lindy
L
Walker
Robert J
RJ
D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D017173:Caenorhabditis elegans / Q000033:anatomy & histology / Q000235:genetics; D029742:Caenorhabditis elegans Proteins / Q000235:genetics; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000502:physiology*; D004347:Drug Interactions; D004576:Electromyography; D019835:FMRFamide / Q000494:pharmacology*; D043802:GTP-Binding Protein alpha Subunits, Gq-G11 / Q000235:genetics; D066298:In Vitro Techniques; D007546:Isoquinolines / Q000494:pharmacology; D009154:Mutation / Q000502:physiology; D010609:Pharyngeal Muscles / Q000187:drug effects*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D054799:Phospholipase C beta / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D012701:Serotonin / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology; D007212:Indolizines; D011720:Pyrazoles
D003994:Bucladesine; D029742:Caenorhabditis elegans Proteins; D005576:Colforsin; D000242:Cyclic AMP; D019835:FMRFamide; D043802:GTP-Binding Protein alpha Subunits, Gq-G11; D007546:Isoquinolines; D010726:Phosphodiesterase Inhibitors; D054799:Phospholipase C beta; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D012701:Serotonin; D013449:Sulfonamides; C479565:Egl-30 protein, C elegans; C087068:KSAYMRFamide; C044388:N-(2-aminoethyl)-5-isoquinolinesulfonamide; C517632:Egl-8 protein, C elegans; C038366:ibudilast; D007212:Indolizines; D011720:Pyrazoles